论文部分内容阅读
目的：研究重组α－２ａ干扰素（酵母）局部注射治疗尖锐湿疣的疗效及安全性。方法：以α－２ａ干扰素（大肠杆菌）作对照，进行了随机、双盲、多中心、对照平行试验。试验组用２％利多卡因１ｍｌ溶解α－２ａ干扰素 １００万 Ｕ，于患者皮损基底部皮内注射，每次１００万Ｕ，每周３次，连续３周，共９次；对照组用同类药α－２ａ干扰素，使用方法与试验组相同。其中试验组入组１１２例，失访１例，可评价病例１１１例，对照组入组１１１例，失访２例，因不符合标准淘汰２例，可评价病例１０７例。结果：试验组１１１例，其中痊愈３８例，显效３３例，进步 ２９例，无效 １１例，痊愈率 ３４．２３％，总有效率 ６３．９６％；对照组 １０７例，其中痊愈２５例，显效３２例，进步３２例，无效１８例，痊愈率２３．３６％，总有效率５３．２７％。两组疗效比较，统计学处理无显著性差异。两组药物不良反应发生率经统计学处理，Ｐ＞０．０５，无显著性差异。结论：提示α－２ａ干扰素（酵母）治疗尖锐湿疣疗效与对照药α－２ａ干扰素（大肠杆菌）相似。
Objective: To study the efficacy and safety of local injection of recombinant interferon α-2a (yeast) in the treatment of condyloma acuminatum. Methods: Randomized, double-blind, multicenter and controlled parallel experiments were performed with α-2a interferon (E. coli) as a control. The experimental group with 1% 2% lidocaine α-2a interferon dissolved 1 million U, intradermal injection at the base of the skin lesions in patients with 1 million U, 3 times a week for 3 consecutive weeks, a total of 9 times; control group With similar drugs α-2a interferon, using the same method with the test group. Among them, 112 cases were enrolled in the trial group, 1 case was lost to follow-up, 111 evaluable cases, 111 cases in the control group and 2 cases lost to follow-up. Results: The experimental group of 111 cases, of which 38 cases cured, effective in 33 cases, 29 cases improved, 11 cases ineffective, the cure rate was 34.23%, the total effective rate was 63.96%; control group of 107 cases, of which 25 cases cured, effective 32 cases, 32 cases improved, 18 cases ineffective, the cure rate was 23.36%, the total effective rate was 53.27%. There was no significant difference between the two groups in the statistical treatment. Two groups of adverse drug reactions incidence by statistical analysis, P> 0.05, no significant difference. CONCLUSIONS: It is suggested that the efficacy of alpha-2a interferon (yeast) in the treatment of condyloma acuminatum is similar to that of the control interferon alpha-2a (E.coli).